Abbott Laboratories stock

ABT · NYSE · USD

$108.52Change from previous close: +1.18%Absolute change: +$1.27

Close · November 13, 2026

Price history

−16.05% over the period

1 year: from $129.26 (November 13, 2025) to $108.52 (November 13, 2026), −16.05%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$108.52
October 30, 2026$106.20
September 30, 2026$98.83
August 31, 2026$110.36
July 31, 2026$105.70
June 30, 2026$90.74
May 29, 2026$85.60
April 30, 2026$90.79
March 31, 2026$102.67
February 27, 2026$116.35
January 30, 2026$109.30
December 31, 2025$125.29
November 28, 2025$128.90
November 13, 2025$129.26

At a glance

  • The company

    Discover, develop, manufacture and sell pharmaceutical, diagnostic, nutritional and medical device products globally

  • Latest results

    Quarter to September 30, 2026 · EPS $1.42 (estimate $1.42)

TickerLandia's take on Abbott Laboratories

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$81.97
52-wk high$132.03

−17.81% from the 52-week high

Analysts · 28 analysts

Average target$118.91+9.57% vs. price

Buy 23 · Hold 5 · Sell 0 · Buy

TickerLandia Fingerprint: Abbott Laboratories

Compared with similar companies: very high dividend.

Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Abbott Laboratories is cheaper than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Abbott Laboratories's P/E today is 29.2, below the median of its last 10 fiscal years (38.3; between 14.8 and 211.4 from 2016 to 2025). Abbott Laboratories's P/E (trailing 12 months): 40.5, +29% against the median of a group of 11 similar companies (31.4).

P/E compared with its history

Compared with 11 similar companies

Abbott Laboratories's metrics compared with similar companies
MetricAbbott LaboratoriesPosition in the groupBand
P/E (trailing 12 months)40.5High
Forward P/E18.3Middle
Operating margin15.6%Low
ROE9.1%Low
Debt/equity0.61Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Abbott Laboratories. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$13.01B

Latest quarter · Q3 2026

Net income

$920M

Latest quarter · Q3 2026

Quarterly net margin

7.1%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$187.95B
P/E
40.5
EPS
$2.68
Volume
6.18M
Daily trading
€911.89M
Dividend yield
2.32%
Last ex-dividend on October 15, 2026

How Abbott Laboratories is changing

All results
  • Revenue grew 5.1% a year on average over the last 5 years

  • Free cash flow equal to 73% of net income

Returns

Abbott Laboratories returns with dividends

$1,000 invested in Abbott Laboratories 5 years ago, on November 15, 2021, would be worth $926 today with dividends reinvested: −7.38% in total, −1.52% per year. On price alone it would be $838 (−16.16%).

PeriodAbbott LaboratoriesS&P 500$1,000 becomes
1 month+5.76%−3.12%$1,058
6 months+29.45%+1.58%$1,295
Year to date−13.38%+10.46%$866
1 year−13.98%+12.23%$860
3 years+20.68%+71.41%$1,207
5 years−7.38%+61.48%$926
10 years+234.00%+249.40%$3,340

Over the last 6 months it has done better than 67% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Abbott Laboratories: technical analysis

Abbott Laboratories shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 23.3% below its highest close since January 2, 1990 ($141.46, December 27, 2021).

Trend
No clear trend
RSI (14 sessions)
54
Between 30 and 70
vs 200-session average
+6.86%

Support and resistance

Price areas where Abbott Laboratories has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$121.77+12.21%3 touches, last on January 5, 2026
  2. Resistance$117.08+7.88%3 touches, last on November 5, 2026
  3. Resistance$110.61+1.93%2 touches, last on July 29, 2026
  4. Last price$108.52
  5. Support$104.55−3.66%3 touches, last on September 22, 2026
  6. Support$100.61−7.29%2 touches, last on September 17, 2026
  7. Support$97.90−9.78%2 touches, last on October 21, 2026

Volatility and risk

Over the last year it has moved little with the S&P 500.

Beta (1 year) vs S&P 500
0.07
Volatility (60 sessions, annualised)
26.2%
Largest fall in the last year
−36.78%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Abbott Laboratories: seasonality

Average monthly price change over 37 years

−0.2%Jan+0.6%Feb−0.2%Mar+1.8%Apr+1.3%May+0.2%Jun+2.0%Jul−0.2%Aug+0.8%Sep+1.8%Oct+2.1%Nov+1.2%Dec

Over the last 37 years, the strongest month for Abbott Laboratories has been November: +2.12% on average, positive in 26 years out of 36. The weakest has been August: −0.23% on average, positive in 23 years out of 37.

Show chart data
MonthAverageMedianPositive years
January−0.15%−0.18%18 of 36
February+0.62%+1.34%20 of 37
March−0.18%−0.22%18 of 37
April+1.75%+1.26%23 of 37
May+1.30%+1.48%23 of 37
June+0.19%+0.73%21 of 37
July+1.99%+2.10%24 of 37
August−0.23%+0.70%23 of 37
September+0.84%+0.65%21 of 37
October+1.76%+1.86%23 of 37
November+2.12%+3.02%26 of 36
December+1.24%+1.26%25 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Abbott Laboratories and its competitors

With 122,000 employees, the group develops and sells products across four segments: generic pharmaceuticals, anti-infective drugs and influenza vaccines, laboratory and point-of-care diagnostic systems, and nutritional and medical devices. Its diagnostics range includes molecular tests for HIV, SARS-CoV-2, influenza, RSV and strep A, as well as drug and alcohol tests. Its nutritional line covers pediatric and adult formulas and infant formula, while its devices address heart rhythm management, heart failure, vascular and structural heart conditions, neuromodulation and diabetes care through glucose monitoring systems.

Headquarters
Abbott Park, United States
Employees
122,000
Founded
1888
Chief executive
Robert Ford
Abbott Laboratories and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Abbott LaboratoriesABT$187.95B15.6%40.5+29.45%
MedtronicMDT$131.57B20.1%25.3+34.97%
StrykerSYK$117.88B24.0%33.0+2.50%
Boston ScientificBSX$64.27B19.6%18.7−16.43%
Edwards LifesciencesEW$61.61B28.8%61.6+31.65%
GE HealthCare TechnologiesGEHC$37.54B13.8%17.6+34.14%

Same industry or related industries, similar size. Compare Abbott Laboratories with its competitors · Full profile